Masaryk Memorial Cancer Institute

Real‐World HRR Testing Pathways and Patterns of Detected Alterations in Prostate Cancer From the Multinational ARON‐3 Study

ABSTRACT Background Homologous recombination repair (HRR) testing is increasingly relevant in prostate cancer because it identifies patients who may benefit from biomarker‐guided treatment strategies, including poly(ADP‐ribose) polymerase inhibitors (PARPi). However, real‐world i...

Sacituzumab govitecan in heavily pretreated metastatic triple-negative breast cancer: a secondary analysis of the CEBCC-102 real-world cohort

Abstract Background Real-world evidence on sacituzumab govitecan (SG) in heavily pretreated patients with metastatic triple-negative breast cancer (mTNBC) remains limited. This study assessed SG outcomes in a multicentre Central European cohort. Methods This retrospective study i...

High-grade serous ovarian cancer is associated with increased TP53 mutation burden in uterine lavage

High grade serous ovarian cancer (HGSC) has low survival partly due to the lack of methods for detection, diagnosis, and risk prediction. TP53 mutations, which drive HGSC, are found in gynecological tissues as the result of somatic evolution, but it is unknown whether an excess o...

Ovarian cancer tumor immune microenvironment and its clinical trial implications

Abstract Ovarian cancer is the most lethal gynecologic malignancy, primarily because of late-stage diagnosis, rapid disease progression, and marked molecular and immunologic heterogeneity. It remains the leading cause of gynecologic cancer-related death, affecting approximately 1...

P1.106. Proteomic Signatures of Chemoresistance in Oesophageal Adenocarcinoma Cell Models

Abstract Topic Esophageal Cancer: Molecular Biology/Pathology Background Oesophageal adenocarcinoma is a rapidly rising cancer with poor prognosis. Despite advances in surgery, chemotherapy, and targeted therapy, five-year survival remains below 20%. Treatment failure is largely...